Mark Booth currently serves as Chief Commercial Officer of Orexigen Therapeutics. Previously, Mr. Booth was President of Takeda Pharmaceuticals North America (TPNA) where he presided over commercial, medical and scientific affairs, business development and all support functions. Under his leadership, TPNA became one of the fastest growing pharmaceutical companies in the U.S. with sales of over $4B.
Over the course of his career, Mr. Booth has played an integral role in numerous co-development/co-promotional partnerships including Prevacid®, Enbrel® and Actos® which all achieved multi-billion dollar sales status. Prior to his role at TPNA, Mr. Booth served as Senior Vice President, General Manager at Immunex Corporation where he was responsible for the sales, marketing and project management functions until the company was acquired by Amgen in 2002. Before joining Immunex Corporation, Mr. Booth was at Abbott Laboratories where he served in a range of leadership positions including Division Vice President, General Manager for the $1B anti-infective franchise. Mr. Booth holds a B.S. in biology from Northern Illinois University and an M.B.A. from Northwestern University's Kellogg School of Management.
James Tyree is the former President of Abbott Biotech Ventures Inc., where he was responsible for Abbott's (now AbbVie) biotechnology business development projects. Prior to ABVI, Mr. Tyree was Executive Vice President of Pharmaceutical Products Group where he was responsible for Abbott's global pharmaceutical business, including commercial operations, research and development, and manufacturing.
In addition to his executive roles at Abbott, Mr. Tyree was President of Sugen Inc., and has held various leadership positions at other pharmaceutical companies. He is a member of the advisory boards of the University of Chicago Council at Chicago Booth and the University of Chicago ADVANCE. He is a member of the advisory board of the Kellogg Center for Biotechnology at Northwestern University, a member of the Chicago Council on Global Affairs, and Co-Chairman of the Global Health Policy Roundtable. He is past chairman and member of the executive committee of the board of directors of the Illinois Biotechnology Industry Organization, and an executive committee member of the 2010 BIO International Convention. He is also a member of the Economic Club of Chicago.
Tyree earned a Bachelor's degree in psychology and forensic studies and a Master's degree in business administration from Indiana University.
Amy Paller is the Walter J. Hamlin Professor and Chair Department of Dermatology at Northwestern University Feinberg School of Medicine. She received her undergraduate degree and graduate degree in genetics from Brown University, and her M.D. from Stanford University. Dr. Paller completed residency training in both pediatrics and dermatology at Northwestern University, and her research fellowship training at the University of North Carolina.
She is the Assistant Editor of the Journal of the American Academy of Dermatology, Associate Editor of the Journal of Investigative Dermatology, and serves on the editorial boards of several other journals. Dr. Paller is on the scientific advisory boards for several major support organizations for patients, among them the National Eczema Association, the National Psoriasis Foundation, the Foundation for Ichthyosis and Related Skin Types, and the Dystrophic Epidermolysis Bullosa Research Association.
Dr. Paller's research focuses on the role of gangliosides in keratinocyte function and topical application of SNA constructs for gene regulation. She is currently the Principal Investigator of the NIH-funded Northwestern Skin Disease Research Center.
Michael R. Hodges is licensed British Medical Doctor, board certified in internal medicine. Dr. Hodges has twenty four years of biopharmaceutical development experience in both large pharmaceutical and biotechnology companies across a broad range of therapeutic areas, including infectious disease, oncology, respiratory and dyslipidemia.
Most recently, Dr. Hodges was the Chief Medical Officer and VP of Drug Development for Santaris Pharma A/S, a company acquired by Roche Pharma in September 2014. At Santaris, Dr. Hodges led development teams for six antisense oligonucleotide drug candidates. Prior to Santaris, Dr. Hodges was the Chief Medical Officer of Altair Therapeutics, Inc., where he led the development of inhaled antisense oligonucleotides.
Dr. Hodges holds B.Sc. in pharmacology from King's College and M.B.B.S. (Medical Doctorate) from Westminster Medical School. He is a member of the Royal college of Physicians (Internal Medicine).
Oliver von Stein has more than 14 years of executive managerial leadership experience in pharma and biotech. As Chief Scientific Officer and scientific founder of InDex Pharmaceuticals AB, Sweden, he transformed the company from start-up to a value creating biotechnology business with partnered assets and a marketed diagnostic. He led the development of numerous novel immunostimulatory oligonucleotides in the field of inflammation and autoimmune diseases to clinical Phase 3. Prior to co-founding InDex Pharmaceuticals, Dr. von Stein was a Senior Project Leader at MediGene AG and a Project Leader at the Karolinska Institute.
Dr. von Stein is currently Operations Director of Silence Therapeutics GmbH. Dr. von Stein holds a B.Sc. in biochemistry from John Moors University (U.K.), M.Sc. in biochemical pharmacology from Southampton University (U.K.) and a Ph.D. in molecular biology from the Karlsruhe Institute of Technology, KIT (Germany).
Jeffrey Raizer completed his undergraduate training at UCLA. He graduated from New York Medical College with an M.D. and then completed two years of internal medicine training at NYU/Bellevue and 3 years of neurology at Yale-New Haven Hospital. He then did a 2 year fellowship in Neuro-Oncology at Memorial Sloan Kettering Cancer Center where he then remained on staff for 5 years before coming to Northwestern University, Feinberg School of Medicine to develop a medical neuro-oncology program. He joined the Neurology department at Northwestern where he is currently a professor. Dr. Raizer serves as Co-Director of the Northwestern Brain Tumor Institute.
Dr. Raizer's research interests are to develop clinical trials using novel agents for patients with primary brain tumors but also metastatic tumors. He is doing research using newer imaging techniques to help management patients and understand responses to treatment. He is also interested in developing quality of life and economic research as it relates to brain tumors. He is currently the PI on 14 clinical trials at NU with more in development and has run over 25 clinical trials in the last 10 years. His future goal is work with translational or basic science research to bring novel therapies into the clinics.
Steven T. Rosen is the first provost and Scientific Director of City of Hope, an independent hospital and medical research center. Prior to City of Hope, he was the Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine, Northwestern University, Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Director of Cancer Programs at Northwestern Memorial Hospital. Following his graduation with distinction from Northwestern University Medical School's Six-Year Honors Program in 1976, Dr. Rosen completed his residency in internal medicine at Northwestern and a fellowship in medical oncology at the National Cancer Institute. Dr. Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies.
Dr. Rosen has received numerous grant awards and contracts and has published more than 250 scientific papers. As Director of the Cancer Center, Dr. Rosen has successfully competed for an NCI Cancer Center Support Grant, NCI grants for his laboratory research, an NCI RAID Contract grant for the development of a novel purine analog, and grants from the Leukemia and Lymphoma Society of America and the American Cancer Society. Dr. Rosen serves on several editorial boards and is editor-in-chief of Cancer Treatment & Research and Oncology News International. He is a member of all major national associations that focus on oncology and has held leadership positions in the Eastern Cooperative Oncology Group, the American Association of Cancer Institutes and the National Comprehensive Cancer Network.
Dr. Rosen was the recipient of Northwestern University Medical School's Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996) and recognition from the Woman's Board of Northwestern Memorial Hospital for Compassionate Care (1996). He is acknowledged in Best Doctors in America.
Robert P. Schleimer majored in Biology at The University of California, San Diego and received a Ph.D. in pharmacology and toxicology at UC Davis. He received post-doctoral fellowship training at the Johns Hopkins University School of Medicine in the Division of Clinical Immunology. Dr. Schleimer joined the faculty at Johns Hopkins and rose through the ranks to become Professor of Medicine.
Dr. Schleimer moved to Chicago to become the Roy and Elaine Patterson Chair and Chief of the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine in 2004. Dr. Schleimer has published over 260 papers and edited numerous books and journal supplements. Dr. Schleimer has trained over 35 post-doctoral fellows and graduate students during his research career, most of whom have gone on to become established investigators in academia and industry. Dr. Schleimer was recognized as one of the most highly cited researchers of the last two decades worldwide by The Institute for Scientific Information (ISI). Dr. Schleimer has served on numerous journal review boards and committees at the National Institutes of Health and has recently been Chair of the Lung Cell and Molecular Immunology Study Section and the Severe Asthma Research Program Study Section.
Dr. Schleimer's laboratory has received continuous NIH funding for over 25 years and he is a recent recipient of a prestigious NIH MERIT award from the National Heart Lung and Blood Institute. Dr. Schleimer has been on the Scientific Advisory Boards of over a dozen pharmaceutical companies, including big pharma and start-ups. He has also been on advisory boards for the NIH, Johns Hopkins, Duke, University of Wisconsin and numerous professional societies. He is presently actively involved in studying the cellular and molecular mechanisms of allergic disease.
Freddy Boey is the current Deputy President and Provost at Nanyang Technological University (NTU) in Singapore. From 2005 to 2010, he was Chair of NTU's School of Materials Science & Engineering, building the school into one of the world's largest research intensive Materials Science & Engineering departments. He has made significant research contributions in the use of functional biomaterials for developing medical devices capable of drug release, for cardiovascular, ocular, and surgical implants. Dr. Boey holds 27 primary patents, many of which have been licensed to the five venture-backed, start-up companies he has founded. These patents derive from the research platform he built at NTU, based on the major grants he championed and won. In the last four years, Dr. Boey was granted more than $42MM, including a prestigious $10MM individual National Research Foundation (NRF) grant for his work on fully biodegradable cardiovascular implants and a $20M NRF Technion-Singapore grant for his research in nanomedicine for cardiovascular diseases. Among his many accolades, Dr. Boey was awarded Singapore's Public Administration Silver Medal by the Government of Singapore in 2010. He is a founding Fellow of the Academy of Engineering Singapore and serves as a Board Director in IPOS, under the Ministry of Law, and in the Defense Science Organization under the Ministry of Defense.
Dr. Boey received a Bachelor's degree of materials engineering from Monash University and a Ph.D. in chemistry and engineering from National University of Singapore.
Craig J. Mundie is Senior Advisor to the CEO at Microsoft and its former Chief Research and Strategy Officer. He started in the consumer platforms division in 1992, managing the production of Windows CE for hand-held and automotive systems and early console games. In 1997, Mundie oversaw the acquisition of WebTV Networks. He has championed Microsoft Trustworthy Computing and digital rights management. In April, 2009, President Obama named Mundie as a member of his President's Council of Advisors on Science and Technology (PCAST).
In 1970, Mundie began his career as an operating system developer for the Data General Nova computer at Systems Equipment Corporation. SEC was subsequently acquired by Data General Corporation, where Mundie later became director of its advanced development facility in Research Triangle Park, North Carolina. In 1982, he co-founded Alliant Computer Systems, holding a variety of positions there before becoming Chief Executive Officer. Alliant filed for bankruptcy in 1992.
Mundie holds a Bachelor's degree in electrical engineering (1971) and a Master's degree in information theory and computer science (1972) from Georgia Tech.